ClinicalTrials.gg
Not yet recruitingNCT06942377Updated Jul 8, 2025

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

A Phase 2 interventional study of Amlodipine in Endometrial Cancer, sponsored by Peking University People's Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Endometrial Neoplasms by Peking University People's Hospital — 15 open to participants now, 15 under way, none of them phase 3. Endometrial Neoplasms · Peking University People's Hospital.

Planned enrollment
8th of 18
140 · median 94
Started
2025
with 3 others
Phase 2
5 of 19
5 open now
Primary completion
2027-01
later than 8 of 14 live
Registered
15th of 19
by date

Among the 19 studies in Endometrial Neoplasms by Peking University People's Hospital, this one is the 8th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 8 of the 14 other live ones, and was the 15th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

15 of the 19 studies in Endometrial Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Endometrial Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Amlodipine in patients with early endometrial carcinoma (EEC) for conservative treatment.

Read the detailed description

After diagnosed of EEC by hysteroscopy, patients meet the study criteria will be enrolled. The age, height, weight, waistline, blood pressure, drug load, basic history of infertility and family cancer will be collected. Blood tests, including calcium, albumin, fasting blood glucose (FBG), fasting insulin (FINS), blood lipids, sex hormone levels, anti-müllerian hormone (AMH) and renal/liver function tests will be performed before treatment to evacuate their basic conditions.

Patients with endometrial cancer who met the inclusion criteria were randomly divided into the control group and the experimental group in a 1:1 ratio according to the random numbers generated in advance. The administration regimen for the two groups was as follows:

Control group: progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa 3.75mg subcutaneous injection monthly); Trial group: progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine (oral Amlodipine 5mg/ day); The specific selection of progesterone regimen was based on whether the patients had oral progesterone contraindications and if BMI≥28kg/m2 was not suitable for oral progesterone, Mirena +GnRHa regimen was selected. The choice of Amlodipine is based on the results that Amlodipine can inhibite growth in several endometrial cancer cells, PDX model and patient-derived cells.

For patients remained SD after 9 months of treatment but refused hysterectomy, a multiple disciplinary discussion would be held for individual case, and alternative treatment would be given. Maintenance treatment will be recommended for patients with CR, and participants will be followed up for at least 1 year.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • endometrial cancer
  • calcium channel blocker
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological diagnosis of endometrial adenocarcinoma G1-2 of the endometrium
  2. If the pathology is endometrial cancer, MRI or ultrasound confirms that the lesion is limited to the endometrium or invading the muscle\<1/2, that is, FIGO (2009) stage IA
  3. Age ≤ 45 years old
  4. Require those who wish to retain their reproductive function to sign
  5. No serious internal medicine complications (severe liver and kidney dysfunction)
  6. No for progesterone treatment or pregnancy
  7. Has not experienced hypotension more than three times in the past six months and can be regularly monitored for blood pressure
  8. Imaging shows no evidence of distant
  9. A. Initial treatment patients: have not used any protective treatment drugs (progestogens, GNRH-a); B. One course of treatment (12 weeks) with incomplete remission of the lesion (partial remission, persistent or progressive lesion); C. Two courses of treatment (24 weeks) with incomplete remission (partial remission, persistent or progressive lesions);

Exclusion criteria

Exclusion Criteria:

  1. Tumor invasion of muscle layer>1/2, FIGO (2009) stage IB or above
  2. Tumor differentiation into G3 or non endometrioid adenocarcinoma
  3. Merge malignant tumors from other parts
  4. Individuals with to conservative treatment or medication use
  5. Patients known to have experienced hypotension
  6. Patients who have taken other types of antihypertensive drugs regularly in the past
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • No intervention
    Participant Group

    Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or mirena +GnRHa 3.75mg subcutaneous injection monthly)

  • Experimental
    Amlodipine Intervention

    Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine 5mg/day. If the patient's blood pressure is higher than 140/90mmHg at 5mg/d, the dose of amlodipine can be increased to 10mg/day

    Drug: Amlodipine

Interventions

  • Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine

06

What researchers measure

Primary outcomes

  1. Pathological cumulative complete response rate after 6 months treatment

    No endometrioid carcinoma or any proliferative lesion is found by pathology; imaging examination shows no evidence of a tumor

    Time frame: Day 1:take medication orally every day;Every three months, undergo hysteroscopy to obtain endometrium for HE and IHC of ER/PR; assessed up to 6-7 months

Secondary outcomes

  1. Recurrence rate

    After complete remission, there is evidence of recurrence in pathology, and the imaging examination shows that the lesion recurrences.

    Time frame: Day 1:take medication orally every day;Every three months, undergo hysteroscopy to obtain endometrium for HE and IHC of ER/PR; up to 12 months after the end of treatment.

  2. Pathological cumulative complete response rate after 12 months treatment

    The ratio of woman achieved CR after 12 months treatment

    Time frame: assessed up to 12 months

  3. Pregnancy rate

    A pregnancy test shows pregnancy after CR.

    Time frame: Day 1:take medication orally every day;Every three months, undergo hysteroscopy to obtain endometrium for HE and IHC of ER/PR; Through study completion, an average of 1 year

  4. Pathological biomarker

    pathological markers(such as Ki-67, estrogen receptor, progesterone receptor, p53, PTEN, MLH1, PMS2, MSH2, and MSH6) at each hysteroscopy

    Time frame: Day 1:take medication orally every day;Every three months, undergo hysteroscopy to obtain endometrium for HE and IHC of ER/PR; Through study completion, an average of 1 year

  5. Adverse reactions

    Any unfavorable response resulting from the administration of any pharmaceutical agent utilized as part of the therapeutic regimen.

    Time frame: Day 1:take medication orally every day;Every three months, serological testing confirms the effects of drugs on the liver and kidneys; Through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jan 2027, 17 months later.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 17 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Apr 24, 2025
StartEst.
Jul 15, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942377
Responsible party
Wang Jianliu (Peking University People's Hospital, Peking University People's Hospital) — Principal investigator
First posted
Apr 24, 2025
Start date
Jul 15, 2025 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 8, 2025

Study contacts

Wang JL Prof. Wang Jianliu, Ph.d
Contact
wangjianliu1203@163.com
0086-010-88324381
Huang Dr. Huang Ting, ph.d
Contact
18817819137@163.com
010-88324474 ext. 18817819137

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion